We are #hiring a working student in #communications!. Are you creative, communicative, and ready to dive into the world of #biotech? Join our #PR and #IR team in Gräfelfing, just outside of Munich! ✨. Curious about public and investor relations at #Immunic, learn more here: .👉

🧠 Cold sores and MS? An intriguing new link. While the connection between #EpsteinBarr virus (#EBV) and #MultipleSclerosis (#MS) is well-established, new research from the University of Illinois Chicago highlights another virus with potential MS relevance: #herpes simplex virus

🎥 Q2/2025 Financials & Corporate Highlights. In a new video interview with @proactive_x, our CEO Dr. Daniel Vitt discussed our latest second quarter financial results and shared updates on the recent progress across our clinical development pipeline. 👉 Watch the full video

RT @proactive_x: Immunic CEO on strong Q2 progress with vidofludimus calcium trials for MS @ImmunicInc #Health #Pha….

🔔 Today, we reported our Q2 2025 financial results and provided a corporate update. Key takeaways:. 🔬 Substantially reduced 24-week confirmed disability worsening in phase 2 #CALLIPER trial in progressive #MS (#PMS), reinforcing our lead asset's neuroprotective potential and

🧫 "One sometimes finds what one is not looking for." – Sir Alexander Fleming. On this day in 1881, the man who would later discover #penicillin was born. #Fleming’s breakthrough in 1928 didn’t come from a grand plan but from #curiosity, #observation, and a deep belief in the

🎯 Expertise meets continuous learning!. 📊 Our Global Head of Biostatistics, Dr. James Myles, will be attending the Joint Statistical Meetings (#JSM2025) taking place Aug 2-7 in Nashville, TN. 📚 At #Immunic, we rely on the deep knowledge of our in-house experts and we never

📄 New Publication!. 📊 A recent study published in Molecular Metabolism highlights promising preclinical findings: #DHODH inhibition with #Immunic's lead compound fostered immune-protective regulatory T cells (#Tregs) and delayed the progression of type 1 #diabetes (#T1D) in two

🧬 The scientific community and public discourse are buzzing about the therapeutic target #GLP1 (glucagon-like peptid-1)!. 🔬 Did you know? Earlier this year, #Immunic reported that our investigational molecule #IMU856 demonstrated a dose-dependent increase of GLP-1 levels in

🎯 #Immunic in the Spotlight!. 📘 @GBReports featured our CEO, Dr. Daniel Vitt, in its new United States Life Sciences 2025 report! 🧬. 💡Learn more about our lead candidate, #vidofludimus calcium — a potential game-changer for #MultipleSclerosis (#MS) treatment that may also

🧠 This week, we recognized World Brain Day!. To mark the occasion, our CSO, Dr. Hella Kohlhof, sat down with @proactive_x to talk about the importance of early diagnosis and treatment in #MultipleSclerosis (#MS) and how research can help to protect #brain function and quality of

🎙️ Podcast Feature Alert!. #Immunic’s President and COO, Jason Tardio, joined Jon Strum on the RealTalk MS podcast to discuss the promising phase 2 clinical trial results for our lead asset in progressive #MultipleSclerosis (#PMS). 🧠. 🎧 Tune in now:

RT @ImmunicInc: 🧠 Tᴏᴅᴀʏ ɪꜱ Wᴏʀʟᴅ Bʀᴀɪɴ Dᴀʏ 2025!.This year’s theme, Brain Health for All Ages, is a powerful reminder that protecting our #….

RT @proactive_x: World Brain Day: Immunic targets MS with new therapy @ImmunicInc #Health #Brain #Ms #Multiplescler….

🧠 Tᴏᴅᴀʏ ɪꜱ Wᴏʀʟᴅ Bʀᴀɪɴ Dᴀʏ 2025!.This year’s theme, Brain Health for All Ages, is a powerful reminder that protecting our #brain starts early and lasts for a lifetime. At #Immunic, we are committed to advancing brain health through our research in #MultipleSclerosis

RT @RealTalkMS_jon: Jason Tardio, President and Chief Operating Officer of Immunic Therapeutics, joins me to discus….

🏃‍♀️🏃‍♂️ Running together, growing togehter: the $IMUX team at B2Run Munich 2025 🎉. For the 4th year in a row, #Immunic laced up its running shoes and hit the track at this year’s #B2Run in #Munich – and we have never been stronger! With over 20 participants, including colleagues

🏃‍♀️🏃‍♂️ 𝗧𝗼𝗱𝗮𝘆, 𝗶𝘁'𝘀 𝘁𝗶𝗺𝗲 𝘁𝗼 𝗿𝘂𝗻! For the 4th time in a row, the #Immunic team takes part in the #B2Run at the Olympic Park in #Munich! 💪. Go team! 🙌. #WeRun #gemeinsamaktiv $IMUX

RT @RealTalkMS_jon: Immunic Therapeutics believes that vidofludimus calcium does more than just slow disability; it….

RT @RealTalkMS_jon: Jason Tardio, President and Chief Operating Officer of Immunic Therapeutics, joins me to discus….